title: Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
abstract: Malignant solitary fibrous tumors are rare soft-tissue sarcomas. They are considered as low-grade malignancies, but may display metastatic potential in 20% of the cases. In case of metastatic or locally advanced, unresectable disease, standard treatments, like anthracycline-based regimens, are poorly effective. Previous studies suggested that antiangiogenic drugs, such as sorafenib, could be efficient to treat vascular sarcomas and solitary fibrous tumors. Five patients with progressive SFT were included in this phase 2 study, and treated with sorafenib at a dose of 800 mg daily. Two patients out of the five achieved a 9 months disease control with sorafenib, while their disease had progressed within the month preceding their inclusion. Consequently, our data suggest a potential efficacy of sorafenib in SFT, Further investigation is needed to confirm these data.
authors.affiliation: Medical Oncology, Claudius Regaud Institute, Toulouse, France, thibaud.valentin@gmail.com.
authors.forename: T
authors.initials: T
authors.lastname: Valentin
authors.forename: C
authors.initials: C
authors.lastname: Fournier
authors.forename: N
authors.initials: N
authors.lastname: Penel
authors.forename: E
authors.initials: E
authors.lastname: Bompas
authors.forename: L
authors.initials: L
authors.lastname: Chaigneau
authors.forename: N
authors.initials: N
authors.lastname: Isambert
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D054364:Solitary Fibrous Tumors / Q000188:drug therapy*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib